We hope you and your family had a pleasant Holiday season. We wish to thank you for your support during a difficult 2020 and extend our best wishes for the New Year. At Pleco, we had to overcome some obstacles as our laboratories had to close for a while due to the Covid restrictions. Our..
Pleco Therapeutics has initiated a sponsored research program at The University of Texas MD Anderson Cancer Center based upon intellectual property developed at MD Anderson and licensed by Pleco. Despite the ongoing Covid pandemic, Pleco Therapeutics is now taking the next step in developing innovative treatments for leukemia patients. MD Anderson is based in Houston,..
Pleco is pleased to announce the appointment of Brenda Reynolds as member of its independent, non-executive board, effective 20th of May. Brenda has a background as a toxicologist and has extensive experience in global project management in the pharma sector.
Pleco is pleased to announce the appointment of Gerard van Leijenhorst, Debra Ainge and Callum Meikle to the non-executive board of directors. Gerard, Debra and Callum are all senior executives and bring a wealth of international experience in the pharmaceutical industry and in executive coaching and management.
Pleco Therapeutics has signed an agreement whereby Pleco licenses intellectual property developed at The University of Texas MD Anderson Cancer Center with the aim of developing innovative treatments for leukemia patients. MD Anderson is based in Houston, Texas and ranks as one of the world’s most respected centres focused on cancer patient care, research, education..
Oss, 1st October 2019 – The Pleco team is pleased to announce that we have moved to our new office at Pivot Park in Oss, Noord-Brabant. The Pivot Park ecosystem consists of a vibrant pharmaceutical R&D community and offers an excellent environment for starting companies. Feel free to contact us if you like to visit..